Haisco(SZ:002653)2016-07-25 16:00Financial Performance - The company's operating revenue for the first half of 2016 was CNY 667,196,535.20, representing a 20.62% increase compared to CNY 553,156,634.85 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was CNY 237,645,680.22, an increase of 10.67% from CNY 214,742,322.16 year-on-year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 135,042,053.47, a decrease of 24.44% compared to CNY 178,720,272.62 in the previous year[21]. - The net cash flow from operating activities was CNY 170,524,527.08, up 21.91% from CNY 139,876,644.86 in the same period last year[21]. - The total assets at the end of the reporting period were CNY 3,377,465,770.01, reflecting a 4.65% increase from CNY 3,227,546,193.04 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company decreased by 5.30% to CNY 2,042,395,007.12 from CNY 2,156,604,841.49 at the end of the previous year[21]. - The basic earnings per share for the first half of 2016 was CNY 0.22, a 10.00% increase from CNY 0.20 in the same period last year[21]. - The diluted earnings per share also stood at CNY 0.22, reflecting a 10.00% increase compared to CNY 0.20 in the previous year[21]. - The weighted average return on equity increased to 11.32% from 9.86% year-on-year, marking an improvement of 1.46%[21]. Research and Development - The company invested CNY 78.9 million in R&D, which is a slight increase of 0.96% year-on-year[35]. - The company obtained 14 clinical approval documents, including for HSK3486, and completed 3 clinical submissions for new formulations[36]. - The company secured exclusive patent rights for MBN-101, a novel antibiotic for chronic wound infections, in China[30]. - The company plans to continue its focus on international collaborations and innovative drug development[30]. Market and Sales - The company's sales revenue reached CNY 667.2 million, representing a year-on-year growth of 20.6%[31]. - Sales expenses surged by 188.35% to CNY 168.9 million due to increased marketing efforts[35]. - The company achieved a gross margin of 71.16% in the pharmaceutical sector, up by 2.51% from the previous year[38]. - The company expanded its market presence by establishing an OTC division and integrating sales channels[36]. Investments and Fundraising - The total investment amount during the reporting period was ¥8,113,125, a decrease of 27.40% compared to the previous year's investment of ¥11,175,660.80[42]. - The total amount of raised funds was ¥73,704.4 million, with ¥694.68 million invested during the reporting period and a cumulative investment of ¥46,236.07 million[53]. - The cumulative amount of raised funds that have been repurposed reached ¥22,644.5 million, accounting for 30.72% of the total raised funds[53]. - The new product production base project has a total investment commitment of ¥25,751.69 million, with ¥17,138 million invested, achieving 100% of the planned investment[54]. - The multi-phosphatidylcholine raw material drug expansion project has a total investment of ¥3,490.6 million, with full investment completed[54]. - The sodium fusidate raw material drug expansion project has only invested ¥2,638.8 million out of a total commitment of ¥9,100.8 million, indicating a significant shortfall[54]. - The marketing network expansion project has fully utilized its committed investment of ¥5,879 million[54]. Financial Position - The total liabilities increased to CNY 1,335,022,724.98 from CNY 1,070,941,351.55, representing a growth of approximately 24.7%[130]. - The company's total equity remained stable at CNY 2,042,443,045.03, unchanged from the previous period[130]. - The company's cash and cash equivalents decreased to CNY 1,159,113,539.04 from CNY 1,194,198,756.40, a decline of about 2.9%[128]. - The company's non-current assets amounted to CNY 1,888,896,362.64, slightly up from CNY 1,841,404,706.28, indicating a growth of about 2.6%[129]. - The company reported a significant increase in accounts receivable, which rose to CNY 164,305,700.76 from CNY 27,831,130.27, marking a substantial increase of approximately 490%[128]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[7]. - The total number of ordinary shareholders at the end of the reporting period was 15,839[115]. - Wang Junmin holds 36.99% of shares, totaling 399,550 shares, with 299,662 shares under lock-up[115]. - Fan Xiulian holds 20.69% of shares, totaling 223,465 shares, with 167,599 shares under lock-up[115]. - Zheng Wei holds 15.82% of shares, totaling 170,877 shares, with 128,158 shares under lock-up[115]. - Shen Ping holds 5.77% of shares, totaling 62,363,847 shares, with 31,181,924 shares under lock-up[115]. - Total locked-up shares released during the reporting period amounted to 77,118,410 shares[113]. - The total number of locked-up shares at the end of the reporting period was 499,115,412 shares[113]. Corporate Governance - The company has not engaged in any major litigation or arbitration matters during the reporting period[78]. - There were no asset acquisitions or sales during the reporting period[80][81]. - The company has made commitments regarding shareholding, including a lock-up period for major shareholders lasting 36 months from the listing date[99]. - The company has not engaged in any securities investments or derivative investments during the reporting period[44][50]. - The company has not held any financial enterprise equity or conducted any entrusted loan activities during the reporting period[43][51]. Accounting and Compliance - The financial statements are prepared based on the assumption of going concern, with no significant issues affecting the company's ability to continue operations identified[170]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that the financial statements reflect a true and complete picture of its financial status as of June 30, 2016[172]. - The company recognizes minority interests and losses separately in the consolidated financial statements, ensuring accurate representation of net profit attributable to minority shareholders[181]. - The company applies the equity method for investments in joint ventures, recognizing its share of assets, liabilities, and income[185].